Abstract 314P
Background
There is insufficient evidence on the neoadjuvant use of bevacizumab before interval debulking surgery (IDS) in advanced epithelial ovarian cancer (EOC). We aimed to evaluate the perioperative outcomes in a cohort of women who underwent IDS after receiving bevacizumab added to neoadjuvant chemotherapy (Bev-NACT).
Methods
We retrospectively reviewed the medical records of all women with advanced EOC who underwent IDS between March 2021 and June 2022 after receiving Bev-NACT at Tata Medical Center. Relevant information was extracted from electronic medical records. Appropriate descriptive and survival statistics were used in the analysis.
Results
A total of 33 women underwent IDS after Bev-NACT. Stage IIIC, stage IVA, and stage IVB disease were present in 51.5%, 12.1%, and 36.4% of cases. The most common histology was high-grade serous carcinoma (95%). The median number of bevacizumab cycles received was 3 (2-5). The objective response rate with Bev-NACT was 90.9%. Complete cytoreduction at IDS was achieved in 75.8%. Chemotherapy response score was 1 in 6.1%, 2 in 72.7%, and 3 in 21.2%. Surgical complications of Clavien-Dindo grade 3 or higher occurred in 24.2% of patients. Serious adverse events attributable to bevacizumab occurred in 12.1% (fistula 3%, wound complications 3%, venous thromboembolism 3%, haemorrhage 3%), and the 30-day postoperative death rate was 3%. Median progression-free survival (PFS) was 23 months (95% CI 18-34), and the estimated 3-year PFS rate was 32%.
Conclusions
Bevacizumab added to neoadjuvant chemotherapy before IDS for advanced EOC had an acceptable safety and promising efficacy. Neoadjuvant bevacizumab in advanced EOC needs to be further evaluated in prospective studies.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
217P - Conditional reprogramming of urine-derived bladder cancer cells: A model for precision medicine
Presenter: Yu Dong
Session: Poster Display
Resources:
Abstract
218P - Clinical effectiveness of tislelizumab combined with gemcitabine/cisplatin (GC) versus GC as adjuvant therapy in high-risk muscle-invasive urothelial carcinoma (MIUC): A real-world study
Presenter: xingliang Tan
Session: Poster Display
Resources:
Abstract
219P - Clinical effectiveness of tislelizumab plus TKI as first-line therapy in patients with metastatic renal cell carcinoma (mRCC): A real-world study
Presenter: Pei Dong
Session: Poster Display
Resources:
Abstract
220P - Heterogeneity in tertiary lymphoid structures predicts distinct prognosis and immune microenvironment characterizations of clear cell renal cell carcinoma
Presenter: Wenhao Xu
Session: Poster Display
Resources:
Abstract
221P - Genetic polymorphism of genes encoding cytokines interleukin1 1-alpha and TNF-alpha in non-muscle invasive bladder cancer
Presenter: Anil Kumar
Session: Poster Display
Resources:
Abstract
222P - The association between response to enfortumab vedotin and peripheral neuropathy: A multicenter retrospective study in Japan
Presenter: Nozomi Hayakawa
Session: Poster Display
Resources:
Abstract
223P - Patient and healthcare practitioner preferences for treatments in advanced renal cell carcinoma
Presenter: Niara Oliveira
Session: Poster Display
Resources:
Abstract
224P - WUTSUP-01: Phase II trial of neoadjuvant toripalimab and chemotherapy in locally advanced upper tract urothelial carcinoma
Presenter: Yige Bao
Session: Poster Display
Resources:
Abstract
225P - A novel multianalyte signature for stratifying Indian non-muscle invasive bladder cancer: A single center observational study
Presenter: Hari P S
Session: Poster Display
Resources:
Abstract
226P - Prognosis stratification of immunotherapy by a mutational signature in urothelial carcinoma
Presenter: Xuebing Han
Session: Poster Display
Resources:
Abstract